The Amicus Therapeutics Inc (FOLD) Stock expansion path ahead
Morgan Stanley raised the price target for the Amicus Therapeutics Inc (NASDAQ:FOLD) stock from “an Equal-weight” to “an Overweight”. The rating was released on December 19, 2023, according to finviz. The research report from Goldman has resumed the stock to Neutral, with a price target set at $11. The stock was upgraded by SVB Leerink, […]
Why Amicus Therapeutics Inc (NASDAQ:FOLD) Stock went up 4.72% in Last Year?
Morgan Stanley raised the price target for the Amicus Therapeutics Inc (NASDAQ:FOLD) stock from “an Equal-weight” to “an Overweight”. The rating was released on December 19, 2023, according to finviz. The research report from Goldman has resumed the stock to Neutral, with a price target set at $11. The stock was upgraded by SVB Leerink, […]
Amicus Therapeutics Inc (NASDAQ:FOLD) stock Market Value Reached at $3.36 billion: What Happened?
Morgan Stanley raised the price target for the Amicus Therapeutics Inc (NASDAQ:FOLD) stock from “an Equal-weight” to “an Overweight”. The rating was released on December 19, 2023, according to finviz. The research report from Goldman has resumed the stock to Neutral, with a price target set at $11. The stock was upgraded by SVB Leerink, […]
Amicus Therapeutics Inc (NASDAQ:FOLD) stock Posted Operating Margin of -18.40 percent in Last Year: Is Admissible?
Morgan Stanley raised the price target for the Amicus Therapeutics Inc (NASDAQ:FOLD) stock from “an Equal-weight” to “an Overweight”. The rating was released on December 19, 2023, according to finviz. The research report from Goldman has resumed the stock to Neutral, with a price target set at $11. The stock was upgraded by SVB Leerink, […]
What does the future hold for Amicus Therapeutics Inc (FOLD) Stock?
Morgan Stanley raised the price target for the Amicus Therapeutics Inc (NASDAQ:FOLD) stock from “an Equal-weight” to “an Overweight”. The rating was released on December 19, 2023, according to finviz. The research report from Goldman has resumed the stock to Neutral, with a price target set at $11. The stock was upgraded by SVB Leerink, […]
